Divalproex Extended‐Release in Adolescent Migraine Prophylaxis: Results of a Randomized, Double‐Blind, Placebo‐Controlled Study

Abstract

In the current study, divalproex sodium extended-release did not differentiate from placebo in the prophylactic treatment of migraine headaches but was generally well-tolerated in adolescents aged 12 to 17 years.